

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7571444

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CYDEX PHARMACEUTICALS, INC.	07/27/2009
RECEIVING PARTY DATA	
Name:	PRISM PHARMACEUTICALS, INC.
Street Address:	1150 FIRST AVENUE
Internal Address:	SUITE 1050
City:	KING OF PRUSSIA
State/Country:	PENNSYLVANIA
Postal Code:	19406
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16043833
CORRESPONDENCE DATA	
Fax Number:	(949)760-9502
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	9497600404
Email:	efiling@knobbe.com
Correspondent Name:	KNOBBE MARTENS OLSON AND BEAR LLP
Address Line 1:	2040 MAIN STREET
Address Line 2:	14TH FLOOR
Address Line 4:	IRVINE, CALIFORNIA 92614
ATTORNEY DOCKET NUMBER:	LIGAN4.015C4
NAME OF SUBMITTER:	MARK RUBINSHTEIN
SIGNATURE:	/Mark Rubinshtein/
DATE SIGNED:	10/03/2022
Total Attachments: 2	
source=assignment - LIGAN4.015C4 (Cydex to Prism)#page1.tif	
source=assignment - LIGAN4.015C4 (Cydex to Prism)#page2.tif	

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration, receipt of which is hereby acknowledged, Prism Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware and having an office and place of business at 1150 First Avenue, Suite 1050, King of Prussia, Pennsylvania 19406 (hereafter referred to as the "Assignor"), hereby sells and assigns to CyDex Pharmaceuticals, Inc., a corporation formed under the laws of Delaware, having an office and place of business at 10513 W. 84th Terrace, Lenexa, Kansas 66214-1643 (hereafter referred to as the "Assignee"), its entire right, title and interest for the United States of America (as defined in 35 U.S.C. § 100), and throughout the world, including the right to sue for past infringement and to collect for all past, present and future damages,

(a) in the invention(s) known as **Formulations Containing Clopidogrel and Sulfoalkyl Ether Cyclodextrin and Methods of Use** for which international application(s) for patent has an international filing date of April 26, 2008 (also known as International Application No. PCT/US/2008/61697), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The Assignor agrees to execute all papers necessary in connection with the applications and Letters Patents as above, and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding applications thereof and also to

execute separate assignments in connection with such applications as the Assignee may deem necessary or expedient.

The Assignor agrees to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the applications or Letters Patents or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application thereof and to cooperate with the Assignee at Assignee's expense in every reasonable way possible in obtaining evidence and going forward with such interference or patent enforcement action.


The Assignor agrees to perform all affirmative acts at Assignee's request and expense that may be necessary to obtain or ensure a grant of a valid patent to the Assignee.

The Assignor hereby represents that Assignor has full right and authority to convey the entire interest herein assigned, and that Assignor has not executed, and will not execute, any agreement in conflict therewith.

The Assignor hereby grants the patent practitioners associated with CUSTOMER NUMBER 26111 the power to insert in this assignment, including the attached Schedule A, any further information regarding the patents and patent applications so identified in such Schedule A that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.


SIGNED on behalf of the said ASSIGNOR,

PRISM PHARMACEUTICALS, INC.

By: 
Name: WARREN COOPER
Title: PRESIDENT & CEO
Date: 7/17/09

SIGNED on behalf of the said ASSIGNEE,

CYDEX PHARMACEUTICALS, INC.

By: 
Name: Theron E. Odlaug, Ph.D.
Title: President and Chief Executive Officer
Date: 7/27/09